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ABSTRACT

The cannabinoid receptors, members of the G-protein coupled receptor (GPCR)
superfamily, have been implicated in numerous human physiological functions and
diseases. These receptors, cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2), are
most concentrated in the central nervous system and immune cells, respectively, and have
each become a target of therapeutic interest. Dual CB1/CB2 agonists such as delta-9tetrahydrocannbinol (THC) have demonstrated efficacy in the treatment of nausea, pain,
and glaucoma, but suffer from psychotropic effects mediated by CB1, motivating the search
for CB2 selective therapeutic agents. Selective modulation of the CB2 receptor has
therapeutic potential in human health disorders such as pain, inflammation, and cancer. In
our efforts to develop CB2 receptor selective ligands, we preliminarily examined a structure
activity relationship (SAR) study of synthetic and natural terpenoid cannabinoids to design
more potent and selective CB receptor ligands. In an effort to expand this SAR, we
synthesized a series of analogs with alternative functional groups and substitution patterns
using a dihydrobenzofuran scaffold, with previous biological assay data guiding the design
of our new compounds. Aldol condensation and Luche reduction reactions were used to
create six new analogs. The structures of the new analogs synthesized were confirmed
using NMR and MS techniques. The compounds were submitted for biological evaluation
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in a radioligand displacement assay for both the CB1 and CB2 receptors. One compound
exhibited modest affinity for the CB2 receptor. The alterations in functional groups and
substitution patterns provided analog data to help create a more comprehensive structure
activity relationship study in the future development of CB2 selective compounds. This
research was funded by Grant Number P20GM104931 from the National Institute of
General Medical Sciences (NIGMS), COBRE-NPN.
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INTRODUCTION

History and Composition of Cannabis Sativa
Cannabis sativa, a hemp plant originating in Asia, is one of the oldest known
mind-altering drug-containing species.1 Historically, the hemp plant has various uses
including weaving its fibers into fabric, producing bowstrings for archers, and
manufacturing of paper.2 During the Sufis movement, cannabis use was reported as a
means of communication with Allah; the founders of this Islamic movement believed this
was only possible in an ecstatic state. Thus, as the popularity of the Sufis movement
increased so did the drug usage. Now some 200-300 million people are estimated to use
cannabis worldwide1 and in the United States usage may increase due to its legalization
and availability as a social drug. With such widespread use of cannabis, researchers were
inclined to study its affects and components to determine its safety and therapeutic
potential. Thus, since 2012, 545 constituents have been identified with 441 defined as
non-cannabinoid and 104 as cannabinoids. Eleven types of cannabinoids or
phytocannabinoids found in the resin and leaves of Cannabis sativa have been classified
as follows: (-)-delta-9-trans-tetrahydrocannabinol (D9-THC), (-)-delta-8-transtetrahydrocannabinol (D8-THC), cannabigerol (CBG), cannabichromene (CBC),
cannabidiol (CBD), cannabinodiol (CBND) cannabielsoin (CBE), cannabicyclol (CBL),
cannabinol (CBN), cannabitriol (CBT) and miscellaneous-type cannabinoids.3 The three
1

main components and more thoroughly researched components of Cannabis sativa are
CBD, CBN and THC (Figure I).1, 4

Figure I. Structures of CBD, CBN, and THC

The Endocannabinoid System
The cannabinoid components of cannabis are known to interact with the
endocannabinoid system, an important and complex signaling system that has regulatory
roles for cells throughout the nervous, immune, and other systems.5 The endocannabinoid
system contains two distinct and critical G-protein coupled receptors (GPCRs) described
as cannabinoid receptor subtype 1 (CB1) and cannabinoid receptor subtype 2 (CB2).
GCPRs are part of a large protein receptor family which are responsible for signal
transduction in cells. They contain seven a-helical transmembrane spanning region with
an extracellular N-terminal and C-terminal cytosolic domain coupled to a G-protein
comprised of a, b and g subunits. Generally, ligands bind to the receptor causing the
subsequent detachment of the b and g subunits which activate an effector enzyme. The
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effector enzyme produces second messengers (e.g. cyclic adenosine monophosphate
(cAMP), calcium and inositol 1-4-5-triphosphate (IP3)).6 The CB1 and CB2 receptors are
thought to operate in a more complex manner for signaling which results from the
inhibition of adenylate cyclase, specific calcium channels, or activation of protein
kinases. This action modulates neurotransmission.

Figure II. Abbreviated neuronal cannabinoid signaling. MAPK = mitogen activated
protein kinases, AC = adenylyl cyclase, cAMP = cyclic adenosine monophosphate, PKA
= protein kinase A.7

Both the CB1 and CB2 receptors were cloned in 1991 and 1992 respectively and
based on their amino acid sequences, were found to be approximately 44% similar
(Figure II).8 The CB1 receptor is mainly present in central and peripheral neurons,
however CB2 receptors are more profoundly expressed in the spleen and immune cells.
3

Originally, CB2 receptors were believed to be relatively absent from the brain, but this
was challenged recently. Researchers have found CB2 protein expression in microglial
cells in the brain and CB2 expression in neurons.9 However, recent studies7 cast doubt on
this conclusion due to discrepancies in validation of antibodies used in immunolabeling
experiments for the CB2 receptor.

Figure III. Structure of CB1 and CB2 receptors.10

Discovery of the cannabinoid receptors lead researchers to question whether there
were endogenous ligands linked to these receptors. Later research uncovered the presence
of endocannabinoids unrelated to the cannabinoid structure found in the hemp plant.
These ligands were derivatives of polyunsaturated fatty acids and were identified as
anandamide (N-arachidonoylethanolamide, AEA), 2-arachidonoylglycerol (2-AG), 2arachidonylglyceryl ether (noladin ether), O-arachidonyl-ethanolamine (virodhamine)
4

and N-arachidonoyl-dopamine (NADA). Anandamide and 2-AG (Figure III) were the
first ligands discovered and are not produced and stored, but synthesized on demand, then
subsequently released.11 Anandamide is a partial agonist of CB1 receptor and nearly
inactive for the CB2 receptor. However, 2-AG is a full agonist of both receptors.
Interestingly these endocannabinoids also have modest affinity for the vanilloid type-1
(TRPV1) channel.12 Animal studies have shown that administration of AEA induces
hypothermia, analgesia, catalepsy, and appetite stimulation.9 Although originally
considered insignificant initially, 2-AG has been linked to the modulation of feeding,
hypotension, neuroprotection and cell proliferation and other interesting physiological
processes.4

Figure IV. Structure of endocannabinoids 2-AG and AEA.
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Cannabinoid and Endocannabinoid Therapeutic Benefits

Although the FDA designation of THC and CBD as Schedule I controlled
substances may obstruct their development as therapeutics, ample studies have shown
these cannabinoids have been shown to offer therapeutic advantages in glaucoma, nausea,
AIDS-associated anorexia and wasting syndrome, multiple sclerosis, chronic pain,
inflammation and epilepsy.13 Cannabidiol, marketed as Epidiolex® has not been
approved by the US-FDA but is currently under evaluation in a phase III clinical trial for
the treatment of seizures in childhood onset epilepsy. In other countries such as Canada
and the United Kingdom, Nabiximols (Sativex ®) has been approved as a treatment
option for neuropathic pain and disturbed sleep and spasticity in patients with multiple
sclerosis. It is administered as an oromucosal spray formulated with THC and CBD
extracts and is currently in phase III clinical trials in the US. About 2.5 million people
worldwide are affected by multiple sclerosis and without a cure, management of the
debilitating symptoms is the goal of treatment.14 However, problems may arise with
providing patients in the US with this treatment option due to federal regulations of THC
as a controlled substance. The cannabis extract containing THC is thought to exert its
therapeutic effects by activation of either CB1 or CB2 receptors.15 However, the
psychoactive effects of cannabis are thought to be due to THC activating the CB1
receptor. Therefore, studies shifted to targeting the CB2 receptor to surpass this major
hurdle by creating ligands that selectively bind to the CB2 receptor. Many studies have
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proposed that a CB2 agonist may be effective in treating a range of conditions and
diseases that have a neuro-inflammatory or neurodegenerative component, such as
multiple sclerosis, amyotrophic lateral sclerosis, Huntington’s disease, and stroke.7,16
Therefore, our efforts were directed towards the design and synthesis of an agonist with
selectivity for the CB2 receptor.

7

Results and Discussion
Design and Synthesis of a Benzofuran Scaffold
My thesis research is a continuation of the graduate dissertation research initially
conceived by Eric Bow, Ph.D. at the University of Mississippi. The search for a CB2
selective modulators began with the design of a scaffold that had spatial similarity to the
potent THC analog (-)-alpha-10a-hydroxy-delta-9-tetrahydrocannabinol (10a-OH THC),
a natural product isolated and characterized from Cannabis sativa by Research Scientists
in COBRE-NPN CORE A (unpublished research).

This naturally occurring

cannabinoid contains a unique hydroxyl substituent at the 10a-position of THC. The
analog was found to have high affinity for both the CB1 and CB2 receptors. 10a-OH THC
was used as a template to create a new scaffold, followed by implementation of a
structure activity relationships (SAR) study. In order to design CB2 selective analogs,
several SAR elements derived from the classical cannabinoids (Figure IV) were
considered, including: i.) etherification of the phenol to decrease CB1 affinity without
effecting CB2 binding; ii.) variation of ring sizes and substitution patterns in place of the
“Northern” cyclohexane ring, and; iii.) substitution in the “Southern” dimethyl pyran
ring.

8

Figure V. SAR elements of classical cannabinoids.

These features described in conjunction with molecular modeling tools resulted in
the decision to employ a dihydrobenzofuran scaffold, depicted in Figure VI.6
Computational superimposition underlined the similarities in interaction areas of the two
molecules (Figure VII). The furan oxygen and 3-hydroxy group of the
dihydrobenzofuran scaffold overlapped with the phenol and 10a-hydroxy group of 10aOH THC.6 This suggested that this novel scaffold may serve as a viable surrogate of the
classical cannabinoids and engage in similar binding interactions with CB receptors.

OH
OH
OH
O

H
O
(a) -10a-OH- D9-THC

EWB-5-1

Figure VI. Structure of (alpha)-10a-OH-delta-9-THC and dihydrobenzofuran
analog.
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Figure VII. Computational superimposition of 10a-OH THC and 3-hydroxydihydrobenzofuran. 3D Overlay of 3-hydroxy-dihydrobenzofuran scaffold and 10a-OH
THC minimized energy structures in Chem3D 15.0 (Perkin-Elmer). Structures of those
used in simulation are shown left in corresponding colors.6

Using the dihydrobenzofuran scaffold, a series of analogs were proposed in order
to create a small library of compounds for SAR analysis. Each analog was devised by
manipulating the “Western half” or “Eastern half” of the 3-hydroxy-dihydrobenzofuran
or “hydroxyl-aurone” core (Figure VIII). The “Eastern half” was modified by
experimenting with the addition of various aryl-containing building blocks to the scaffold
by aldol condensation reactions and subsequent Luche reductions. In addition, the
“Western half” was altered by changing the nature and position of the alkyl chains. To
synthesize these modified ligands, an analog with the desired alkyl chain length, thought
to be optimal for CB receptor binding, was synthesized first. This lead compound was
then used as a starting point to create several molecules with variations in the phenyl ring
of the “Eastern half” using a substituted benzaldehyde in an aldol condensation reaction.
10

Figure VIII. Structural map of 3-hydroxy-dihydrobenzofuran scaffold.

Synthesis of benzofuran-3(2H)-one
Based on Dr. Bow’s synthetic library of compounds synthesized and evaluated for
CB binding, it was speculated that more potent and selective CB ligands may be realized
with manipulation of alkyl chain substitution, in particularly the regiochemistry of alkyl
chain substitution. As a result, we proposed to synthesize analogs containing alkyl chains
in the 7 versus the 6 position on the dihydrobenzofuran aromatic ring. This new
substituted scaffold would then be subject to subsequent aldol condensation reactions as
preformed in previous compound synthesis.
The synthetic protocol for the 7-substituted dihydrobenzofuran scaffold began
with the nucleophilic addition of n-butyllithium to commercially available 2hydroxybenzaldehyde (1), which afforded the desired addition product (2) in high yield
(Figure IX). Elimination of the secondary alcohol with catalytic perchloric acid and in
situ hydrogenation of the resulting styrene gave 2-pentyphenol (3). Friedel-Crafts
acylation of 3 with chloroacetonitrile under Sugasawa conditions, using BCl3 to direct the
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acylation ortho to the phenol, afforded the a-chloro ketone (4). The substitution pattern
on the aromatic ring of 4 was confirmed by evaluation of the 1H-NMR spectrum.
Cyclization of 4 was accomplished using potassium carbonate as the base to afford the
target scaffold 5.
O

O
Cl

a

b

OH
O

1

c

OH

d

OH

O

OH

OH

2

3

4

5

Figure IX. Synthesis of scaffold 4. Reagents and conditions: (a) n-BuLi, THF, 0 oC, 1 h,
yield: 79.38%. (b) HClO4, Pd/C, H2(g), MeOH, 25 oC, 24 h, yield: 74.47%. (c)
chloroacetonitrile, BCl3, AlCl3, DCM, 25 oC, 24 h yield: 69.75%. (d) K2CO3, DMF, 25
o
C, 1 h, yield: 51.71%.
The advantages of this synthetic pathway were clear: firstly, scaffold 5 was
synthesized in 4 reaction steps with an overall yield of 22%. Secondly, the only product
which required column chromatography purification was the Sugasawa acylation product
4, and thirdly, analogs of 5 with different alkyl substitutions could be synthesized using
the same process with alternate nucleophiles or starting material aldehydes.
With the successful synthesis of the new scaffold 5, we turned our attention to
analog synthesis. It was envisioned that the final target analogs could be obtained rapidly
using an aldol condensation reaction followed by selective 1,2-reduction of the resultant
ketone using Luche reduction conditions (Figure X).
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Figure X. Synthesis of analogs from 7-pentylbenzofuran-3(2H)-one. Reagents and
conditions: (i) acetonitrile and ethylenediamine diacetic acid (EDDA), aldehyde building
block, microwave (1250W power), 2 min. (ii.) NaBH4, CeCl3·7 H2O, methanol or 95%
ethanol, 25ºC, 20 min.

The aldol condensation reaction of 5 and substituted aldehydes was performed in
the presence of ethylenediamine acetate (EDDA) under microwave conditions to afford
benzofuran-3(2H)-ones (6a-b) in reasonable yields. Aqueous workup was not required
prior to purification, as the crude reaction mixtures are typically viscous oils; simple
dilution with ethyl acetate and direct loading onto a silica gel column was required for
purification.
The Luche reduction (NaBH4, CeCl3·7 H2O) of benzofuran-3(2H)-ones (6a; R=F)
resulted in the formation of the desired allyl alcohol (7a). When benzofuran-3(2H)-one
6b (R=NHAc) was subjected to the Luche reduction conditions, the allylic alcohol
product 7b in addition to the rearrangement product 8 was isolated, presumably from the
nucleophilic addition of ethanol to the exo-methylene of 6b via an SN2’ mechanism.

13

One additional set of analogs were also synthesized from the 6-pentylbenzofuran3(2H)-one scaffold 9 previously synthesized by Dr. Eric Bow in the Rimoldi lab. Briefly,
compound 9 was subjected to the aldol condensation with 4-methoxybezaldehye under
microwave heating to afford condensation product 10. Luche reduction of 10 using 95%
ethanol as the solvent afforded a mixture of products (11a and 11b) in modest yields.

Figure XI. Synthesis of analogs from 6-pentylbenzofuran-3(2H)-one (9). Reagents and
conditions: (i) acetonitrile and ethylenediamine diacetic acid (EDDA), 4methoxybezaldehye, microwave (1250W power), 2 min. (ii.) NaBH4, CeCl3·7 H2O,
methanol or 95% ethanol, 25ºC, 20 min.
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Materials and Methods

General Methods
All reactions were monitored for starting material consumption or product
formation using thin-layer chromatography (TLC) techniques and visualized under UV
light (254 nM) or stained with ethanolic p-anisaldehyde, potassium permanganate or
phosphomolybdic acid. Reactants, reagents, and solvents were purchased from
Reactions performed under “standard anhydrous conditions” refers to reactions that
employed flame-dried glassware evacuated and purged with an inert blanket of argon,
and using commercially available anhydrous solvents. Low resolution molecular weight
analysis was preformed using a Waters Micromass ZQ single quadrupole mass
spectrometer with either positive (ESI+) or negative (ESI-) electrospray ionization. A
Bruker 400 MHz Avance Nuclear Magnetic Resonance (NMR) spectrometer was used to
acquire proton (1H) and carbon (13C) NMR spectral data, and the data processed using
MNova (MestReNova) software. Ligands were assessed for putative receptor affinity
using a cannabinoid receptor binding assay conducted by COBRE Core C at the
University of Mississippi. The analogs synthesized were tested in three solutions of
differing concentrations (0.5 µM, 2.5 µM, 10 µM) and run in a competitive radioligand
binding assay against both the CB1 and CB2 receptors. The percent displacement of the
compounds was calculated by considering both the binding of the analog (specific
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binding) and the nonspecific binding using the following formula: 100-(binding of
compound – nonspecific binding) x (100/specific binding).4

Experimental Methods

(2) 2-(1-hydroxypentyl)phenol
Under standard anhydrous conditions, commercially available 2hydroxy-benzaldehyde (1, 872.6 µL, 8.19 mmol) was dissolved in
THF (15 mL) and cooled to 0°C. n-Butyllithium (1 mL, 16.38
mmol) was slowly added dropwise to the solution. The reaction stirred for one hour, and
the solution was diluted with diethyl ether, and quenched carefully with methanol (2 mL).
Water was added and the reaction mixture was placed in a separatory funnel and
extracted 3x with 20 mL of ethyl acetate. The organic layers were combined and washed
with water and brine. The organic layer was dried over magnesium sulfate and
concentrated in vacuo to give 1.17g (79.38%) of 2. MS (ESI+) m/z = 203.28 [M+Na]+.
1

H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.94 (d, J = 7.5 Hz,

1H), 6.84 (q, J = 7.1 Hz, 2H), 4.80 (t, J = 6.6 Hz, 1H), 3.16 (s, 1H), 1.97 – 1.72 (m, 2H),
1.31 (ddd, J = 34.3, 11.4, 4.4 Hz, 4H), 0.91 (t, J = 6.1 Hz, 3H). 13C NMR (101 MHz,
CDCl3) δ 155.37, 128.72, 127.70, 127.20, 119.68, 117.01, 76.00, 36.90, 27.88, 22.48,
13.98.
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(3)

2-pentylphenol
5% Pd/C (100 mg) and 60 mL of methanol were added to
separate Erlenmeyer flasks. 30 mL of methanol was poured
into the flask containing the Pd/C and then transferred to a

round-bottomed flask containing compound 2 (1.17g, 6.50 mmol) and repeated with the
remaining 30 mL of methanol. Three drops of perchloric acid was added to the mixture
and stirring was initiated. The reaction flask was then purged of air and subsequently
saturated with hydrogen gas. After 24 hours, the reaction was halted by filtration of the
Pd/C, rinsing the catalyst repeatedly with methanol, and concentrating in vacuo until
approximately 90% of the methanol was evaporated. The product was extracted with
ethyl acetate, washed with brine, dried over magnesium sulfate, and concentrated in
vacuo to give 1.07 g (74.49%) of 3. 1H NMR (400 MHz, CDCl3) δ 7.19 (d, J = 7.4 Hz,
1H), 7.13 (t, J = 7.7 Hz, 1H), 6.93 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 7.9 Hz, 1H), 5.78 (s,
1H), 2.75 – 2.61 (m, 2H), 1.70 (p, J = 7.4 Hz, 2H), 1.47 – 1.37 (m, 4H), 0.98 (t, J = 6.4
Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.37, 153.68, 130.18, 128.98, 126.92, 120.60,
115.27, 77.46, 77.14, 76.82, 60.97, 31.81, 29.99, 29.56, 22.65, 21.09, 14.13, 14.08.
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(4)

2-chloro-1-(2-hydroxy-3-pentylphenyl)ethan-1-one
Compound 3 (795.30 mg, 4.87 mmol) was dissolved in 5
mL of anhydrous dichloromethane (DCM). Boron
trichloride (680.08 mg, 5.80 mmol) was added to a

separate round-bottomed flask, cooled to 0 oC, and the prepared solution of compound 3,
chloroacetonitrile (438.67 mg, 5.81 mmol), and aluminum trichloride (322.28 mg,
2.42mmol) were added successively. The reaction was allowed to warm to room
temperature and stirred for 24 hours. The reaction was neutralized with 30 mL of 2 N
hydrochloric acid and allowed to stir for one hour. The organic phase was extracted with
DCM, dried over magnesium sulfate and concentrated in vacuo. Silica gel column
chromatography purification (20% ethyl acetate/hexanes) yielded 813.0 mg (69.32%) of
4. MS (ESI+) m/z = 263.08 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 12.01 (s, 1H), 7.55
(dd, J = 8.1, 1.5 Hz, 1H), 7.46 – 7.35 (m, 1H), 6.92 – 6.82 (m, 1H), 4.74 (s, 2H), 2.73 –
2.62 (m, 2H), 1.69 – 1.59 (m, 2H), 1.35 (dt, J = 7.3, 3.8 Hz, 4H), 0.96 – 0.83 (m, 3H). 13C
NMR (101 MHz, CDCl3) δ 137.30, 136.39, 132.76, 127.08, 118.72, 63.59, 45.43, 31.67,
29.47, 28.97, 22.53, 14.03.
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(5) 7-pentylbenzofuran-3(2H)-one
Compound 4 (813.0 mg, 3.38 mmol) and potassium carbonate (933.0
mg, 6.75 mmol) were added to 10 mL of anhydrous DMF. After 3
hours, the reaction was diluted with water and extracted with ethyl
acetate and washed with water and brine. The organic phase was dried
over magnesium sulfate and concentrated in vacuo. Silica gel column
chromatography purification (20% ethyl acetate/hexanes) yielded 356.70 mg (51.71%) of
5. MS (ESI+) m/z = 227.11 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.7 Hz,
1H), 7.42 (d, J = 7.2 Hz, 1H), 7.01 (t, J = 7.5 Hz, 1H), 4.62 (s, 2H), 2.72 – 2.62 (m, 2H),
1.66 (dt, J = 13.7, 8.3 Hz, 3H), 1.36 (dt, J = 7.0, 4.3 Hz, 5H), 0.91 (t, J = 5.6 Hz, 4H). 13C
NMR (101 MHz, CDCl3) δ 200.56, 172.61, 137.38, 128.72, 121.92, 121.30, 120.67,
74.60, 31.52, 29.06, 28.68, 22.46, 14.01.

General Procedure A: Aldol Condensations
Scaffold 5 or 9 (25.0 mg) was added to a glass vial with 1 equivalent of
desired benzaldehyde and 1 equivalent of ethylenediamine diacetic acid (EDDA),
dissolved in 2 mL acetonitrile (ACN). The vial was then microwaved at 50% power
(1250W) for 2 minutes followed by an additional 30-60 seconds, if necessary, to ensure
consumption of starting material by TLC. The reaction was then purified using silica gel
column chromatography.
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General Procedure B: Luche Reductions
The purified aldol condensation product was dissolved in either methanol
or 95% ethanol and was subsequently combined with 1.1 equivalents of cerium (III)
chloride heptahydrate and chilled to 0°C. 1.1 equivalent of sodium borohydride was
added slowly to the solution in equal portions. The reaction was quenched slowly with
water and extracted using ethyl acetate. The organic phase was washed with brine and
dried over magnesium sulfate, and concentrated in vacuo. The crude product was purified
using silica gel column chromatography (ethyl acetate/hexanes mobile phase).

(6a)

(Z)-2-(4-fluorobenzylidene)-7-pentylbenzofuran-3(2H)-one
Synthesized using General Procedure A and 1 equivalent of 4fluorobenzaldehyde. Yield: 73.71% MS (ESI+) m/z = 333.32
[M+Na]+. 1H NMR (400 MHz, CD3CN) δ 8.06 – 7.91 (m, 2H),
7.57 (d, J = 7.4 Hz, 2H), 7.22 (dt, J = 15.2, 8.2 Hz, 3H), 6.82 (s,

1H), 2.90 – 2.80 (m, 2H),1.81 – 1.69 (m, 2H), 1.45 – 1.34 (m, 5H), 0.93 (t, = 7.0 Hz, 4H).
13

C NMR (101 MHz, CD3CN) δ 184.50, 164.45, 146.66, 137.13, 133.54, 133.46, 128.03,

123.70, 121.45, 116.09, 115.87, 110.36, 31.20, 29.03, 28.34, 22.14, 13.32.
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(7a) (Z)-2-(4-fluorobenzylidene)-7-pentyl-2,3-dihydrobenzofuran-3-ol
Synthesized using General Procedure B and 95% ethanol as solvent.
Yield: 46.86% MS (ESI+) m/z = 335.29 [M+Na]+. 1H NMR (400
MHz, CDCl3) δ 7.71 (dd, J = 8.5, 5.7 Hz, 2H), 7.34 (d, J = 7.3 Hz,
1H), 7.18 (d, J = 7.5 Hz, 1H), 7.06 (dt, J = 18.8, 8.1 Hz, 4H), 5.98
(s, 1H), 5.76 (s, 1H), 2.78 – 2.71 (m, 2H), 1.73 (q, J = 7.1 Hz, 3H), 1.45 – 1.39 (m, 4H),
0.95 (t, J = 6.8 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 162.68, 156.67, 155.81, 130.91,
130.17, 130.09, 126.35, 125.71, 122.92, 122.90, 115.44, 115.23, 104.60, 72.83, 31.66,
29.76, 29.28, 22.46, 14.06.

(6b) (Z)-N-(4-((3-oxo-7-pentylbenzofuran-2(3H)ylidene)methyl)phenyl)acetamide
Synthesized using General Procedure A and 1 equivalent of 4acetamindobenzaldehyde. Yield: 69.44% MS (ESI+) m/z =
372.33 [M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J =
8.3 Hz, 2H), 7.57 (d, J = 7.8 Hz, 2H), 7.43 (d, J = 7.4 Hz, 1H),
7.30 (d, J = 7.0 Hz, 1H), 6.97 (t, J = 7.3 Hz, 1H), 6.67 (s, 1H), 5.18 (s, 2H), 2.67 (t, J =
7.4 Hz, 2H), 2.05 (s, 3H), 1.61 (s, 2H), 1.25 (s, 4H), 0.76 (t, J = 5.9 Hz, 3H). 13C NMR
(101 MHz, CDCl3) δ 207.07, 164.23, 146.22, 140.18, 136.58, 132.25, 127.66, 123.22,
121.58, 121.11, 119.49, 112.46, 53.41, 31.34, 28.95, 28.72, 24.23, 22.24, 13.80.
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(7b) (Z)-N-(4-((3-hydroxy-7-pentylbenzofuran-2(3H)-ylidene)methyl)phenyl)acetamide
Synthesized using General Procedure B and methanol as
solvent. Yield: 14.49% MS (ESI+) m/z = 374.37 [M+Na]+. 1H
NMR (400 MHz, CDCl3) δ 7.54 (d, J = 3.3 Hz, 4H), 7.33 (d, J
= 7.4 Hz, 1H), 7.08 (dd, J = 17.2, 7.4 Hz, 2H), 6.52 (s, 1H),
5.66 (s, 1H), 2.86 (t, J = 6.8 Hz, 2H), 2.18 (s, 4H), 1.78 – 1.70 (m, 2H), 1.40 – 1.32 (m,
5H), 0.89 (t, J = 6.7 Hz, 4H).

(8)

N-(4-(ethoxy(7-pentylbenzofuran-2-yl)methyl)phenyl)acetamide
Synthesized using General Procedure B and 95% ethanol as
solvent. Yield: 32.26% MS (ESI+) m/z = 402.71 [M+Na]+.
1

H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H), 7.52 (d, J =8.5

Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.38 – 7.31 (m, 1H), 7.12
(d, J = 7.4 Hz, 1H), 7.06 (d, J =7.2 Hz, 1H), 6.53 (s, 1H), 5.49 (s, 1H), 3.72 – 3.56 (m,
2H), 3.49 (s, 1H), 2.87 (t, J = 7.4 Hz, 2H), 2.16 (s, 3H), 1.72 (p, J = 7.3 Hz, 3H), 1.34 (dt,
J = 7.0, 3.8 Hz, 5H), 1.32 – 1.25 (m, 4H), 0.90 (t, J = 5.6 Hz, 4H). 13C NMR (101 MHz,
CDCl3) δ 168.54, 156.95, 153.87, 137.75, 135.20, 127.93, 127.65, 126.51, 124.07,
122.72, 119.79, 118.45, 104.85, 77.37, 77.06, 76.74, 64.97, 31.59, 29.62,29.38, 24.51,
22.49, 15.30, 14.01.
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(10)

(Z)-2-(4-methoxybenzylidene)-6-pentylbenzofuran-3(2H)-one
Synthesized using General Procedure A, scaffold 9, and 1
equivalent of 4-methoxybenzaldehyde. Yield: 35.69%
MS (ESI+) m/z = 345.51 [M+Na]+. 1H NMR (400 MHz,

CDCl3) δ 7.87 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 7.8 Hz, 1H), 7.13 (s, 1H), 7.02 (d, J = 8.9
Hz, 1H), 6.97 (d, J = 8.9 Hz, 2H), 6.84 (s, 1H), 3.86 (s, 3H), 2.79 – 2.67 (m, 2H), 1.67 (t,
J = 11.2 Hz, 2H), 1.35 (dt, J = 7.6, 3.8 Hz, 5H), 0.94 – 0.87 (m, 3H). 13C NMR (101
MHz, CDCl3) δ 184.15, 166.40, 160.89, 153.68, 146.36, 133.26, 125.18, 124.18, 124.09,
119.72, 114.43, 112.79, 112.29, 55.35, 36.79, 31.37, 30.67, 22.48, 14.19, 13.97.

(11a)

(Z)-2-(4-methoxybenzylidene)-6-pentyl-2,3-dihydrobenzofuran-3-ol
Synthesized using General Procedure B and 95% ethanol
as solvent. Yield: 5.28% MS (ESI+) m/z = 347.43
[M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J =

8.2, 4.5 Hz, 3H), 7.28 (s, 1H), 7.05 (d, J = 8.7 Hz, 1H), 6.94 (d, J = 8.6 Hz, 2H), 6.49 (s,
1H), 5.91 (s, 1H), 3.84 (s, 3H), 2.76 – 2.67 (m, 2H), 1.66 (dt, J = 15.1, 7.5 Hz, 3H), 1.43
– 1.31 (m, 5H), 0.91 (t, J = 6.8 Hz, 4H).
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(11b) 2-(ethoxy(4-methoxyphenyl)methyl)-6-pentylbenzofuran
Synthesized using General Procedure B and 95% ethanol
as solvent. Yield: 17.21% MS (ESI+) m/z = 375.42
[M+Na]+. 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.36 (m,
3H), 7.03 (dd, J = 7.9, 1.3 Hz, 1H), 6.92 (d, J = 8.8 Hz, 2H), 6.50 (s, 1H), 5.46 (s, 1H),
3.83 (s, 3H), 3.70 –3.54 (m, 2H), 2.74 – 2.63 (m, 2H), 1.65 (dt, J = 15.0, 7.5 Hz, 2H),
1.38 – 1.32 (m, 3H), 1.30 (t, J= 7.0 Hz, 5H), 0.90 (t, J = 6.9 Hz, 4H). 13C NMR (101
MHz, CDCl3) δ 159.43, 157.14, 155.58, 139.54, 131.38, 128.54, 125.72, 123.48, 120.39,
113.82, 110.97, 104.41, 77.26, 64.76, 55.28, 36.08, 31.52, 31.40, 22.55, 15.29, 14.02.

Biological Evaluation (COBRE-NPN CORE C)
Cannabinoid receptor assay were conducted by COBRE Core C at The
University of Mississippi. Assays were conducted in accordance with the method
republished below in Tarawneh et al. "Reprinted with permission from Tarawneh, A. et
al., Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the
Respective Radioligands for Human Opioid and Cannabinoid Receptors. Journal of
Natural Products, 2015. 78(6): p. 1461. Copyright (2015) American Chemical Society."
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Cell Culture and Membrane Preparation.
HEK293 cells (ATCC) were stably transfected with plasmids containing
cloned humancannabinoid receptor subtypes 1 and 2 (obtained from Origene, Rockville,
MD, USA). These cells were maintained in a humidified incubator at 37°C and 5% CO2
in a Dulbecco’s modified Eagle’s medium (DMEM) nutrient mixture F-12 HAM
supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 1000 IU/mL penicillin,
and 1000 µg/mL of streptomycin, and 0.5 mg/mL G418 antibiotic solution. Membranes
for the radioligand binding assays were prepared by scraping the cells in cold Tris-HCl,
pH 7.4, and then centrifuged at 5200 g for 10 min at 4°C. The supernatant was discarded,
and the pellet was resuspended in the same buffer, homogenized using a sonic dismembrator model 100 (Fisher Scientific, Pittsburgh, PA, USA) for 30 seconds, and then
centrifuged at 1000g for 10 min at 4°C. The supernatant was saved, and the pellet
underwent the suspension and sonication process two additional times under the same
conditions. The supernatants were combined and centrifuged at 23300g for 40 minutes at
4°C. The pellet was resuspended and aliquoted into 2 mL vials and stored at −80 °C. The
total protein concentration was determined using a Pierce BCA protein assay kit (Thermo
Scientific, Rockford, IL, USA) according to the manufacturer’s instructions. The optimal
membrane and radioligand concentrations for each receptor batch were established
through membrane evaluation and saturation binding experiments.
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Radioligand Displacement Assay for Cannabinoid Receptor Subtypes.
Compounds evaluated in this assay were run in competition binding with
both cannabinoid receptor subtypes, CB1 and CB2. CB receptor binding screening was
performed under the following conditions: 10 µM of each compound from independent
triplicate dilutions was incubated with 1.6975 nM (CB1) or 1.959 nM (CB2). [3H]-CP
55,940, and 5 µg of CB1 or 1 µg of CB2 membrane were incubated for 90 min at 37°C
with gentle agitation in a 96-well plate in a 0.2 mL final volume of 50 mM Tris-HCl, 20
mM EDTA, 154 mM NaCl, and 0.2% radioimmunoassay grade BSA, pH 7.4. The
reaction was terminated via rapid vacuum filtration through a UniFilter 96 GF/C filter
(PerkinElmer Life Sciences Inc., Boston, MA, USA), presoaked with 0.3%
polyethylenimine, followed by 10 washes with 50 mM Tris-HCl, pH 7.4, buffer
containing 0.2% BSA. Filters were dried, 25 µL of MicroScint20 was added, and the
plates were read using a TopCount NXT microplate scintillation counter (PerkinElmer
Life Sciences Inc., Boston, MA, USA). Total binding was defined as binding in the
presence of vehicle (1.0% DMSO). Nonspecific binding was the binding observed in the
presence of 10.0 µM CP-55,940. Specific binding was defined as the difference between
total and nonspecific binding. Percent displacement was calculated using the following
formula: 100-(binding of compound – nonspecific binding) x (100/specific binding).
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Results
Three target analogs were successfully synthesized from the 7pentylbenzofuran-3(2H)-one (5), namely the (Z)-2-benzylidene-7-pentyl-2,3dihydrobenzofuran-3-ols (7a and 7b) and the rearrangement product 8. Two additional
analogs containing a 4-methoxyphenyl group (11a and 11b), and were synthesized from
6-pentylbenzofuran-3(2H)-one (9) (Figure XII). The facile synthesis of these scaffolds
allowed for the implementation of an aldol condensation reaction, performed under
microwave heating, and the Luche reduction reaction, which resulted in some instances,
rearrangement products containing ethanol adducts. The Luche reduction of 10 was
unique insofar as it resulted in sufficient yields of both the allylic alcohol product and
rearrangement product for testing. The structures of the final products and intermediates
were confirmed using NMR spectrometry.
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Figure XII. Series of synthesized ligands subjected to CB binding assay.

CB1 % Displacement
10 µM
2.5 µM
0.5 µM

CB2 % Displacement
10 µM
2.5 µM
0.5 µM

7a

24.3

17.6

14.8

43.3

30.5

14.0

8

59.0

44.9

37.7

83.4

62.2

26.3

7b

0

13.0

15.2

20.1

15.2

15.8

11a

57.1

38.0

37.7

68.9

48.8

32.0

11b

71.9

57.0

36.8

79.6

78.9

56.2

Table I. CB binding data

CB binding assay data results demonstrated that compound 11b had the highest
affinity of the five compounds tested (at 500 nM concentration). Both 4-methoxyphenyl
derivatives derived from the 6-pentyl substituted scaffold, 11a and 11b displayed better
binding affinity with a slight selectivity for the CB2 receptor, more so than with ethoxy
rearrangement. Compared to previously tested compound (3.4), compounds 7b and 8 did
not bind as effectively, suggesting that 7-substitued alkyl chains have a higher
affinity/better fit for both CB receptors. However, 7b and 8 seem to favor binding to the
CB2 receptor in higher concentrations. In addition, the allylic alcohol product seems to
be the least favorable structure for binding affinity (Table II).
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CB1 % Displacement

CB2 % Displacement

10 uM

2.5 uM

0.5 uM

10 uM

2.5 uM

0.5 uM

94.5

*

31.9

96.7

*

57.7

59.0

44.9

37.7

83.4

62.2

26.3

-

13.0

15.2

20.1

15.2

15.8

3.44

8

7b
Table II. Comparison of CB receptor assay binding for compounds 7b, 8 and 3.4
(synthsized by Eric Bow). * = not tested in corresponding concentration. - = 0%
displacement.
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Based on the CB receptor binding data, the analog containing the 4-methoxyphenyl
group in addition to the ethoxy rearrangement (11b) has the greatest potential for CB2
selectivity. The location of the pentyl chain has an influence on CB binding and
selectivity, with 6-alkyl substitution preferred over 7-alkyl substitution. Additional
analogs will be required to build a more complete structure activity relationship analysis.
Although the compound data did not result in the discovery of a CB2 selective compound,
they were very promising and offered a direction for future work towards the discovery
of CB2 selective ligands.
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